TG Therapeutics' (TGTX) Treatment for Chronic Lymphocytic Leukemia Granted Orphan Status by FDA

August 24, 2016 8:22 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

TG Therapeutics' (NASDAQ: TGTX) treatment for chronic lymphocytic leukemia was granted orphan status by the FDA. The generic name is phosphoinositide-3-kinase delta inhibitor.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment